Management of patients with advanced non-small cell lung cancer: role of gefitinib

Código QR

Management of patients with advanced non-small cell lung cancer: role of gefitinib

Vamsidhar Velcheti1, Daniel Morgensztern2,3,4, Ramaswamy Govindan3,41Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA, USA; 2Division of Hematology-Oncology, St. Louis Veterans Hospital, St. Louis, MO, USA; 3Division of Medical Oncology, Washington University School of Med...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vamsidhar Velcheti, Daniel Morgensztern, Ramaswamy Govindan
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/55703b790ac14771a4f891fff26a39f0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
por: Hong Jian, et al.
Publicado: (2017)

Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
por: Gang Chen, et al.
Publicado: (2013)

Glycyrol Alone or in Combination with Gefitinib Is Effective against Gefitinib-Resistant HCC827GR Lung Cancer Cells
por: Shuang Zhao, et al.
Publicado: (2021)

Editorial: New Advances in Non-small Cell Lung Cancer Management: Immune Modulation and Targeted Therapies
por: Thierry Berghmans, et al.
Publicado: (2021)

Advancements in next-generation sequencing for diagnosis and treatment of non-small-cell lung cancer
por: Ying-Qiang Lu, et al.
Publicado: (2017)

The emerging role of nimotuzumab in the treatment of non-small cell lung cancer
por: William Boland, et al.
Publicado: (2010)

Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
por: D&#39;Arcangelo M, et al.
Publicado: (2013)

miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met
por: Xiaonian Cao, et al.
Publicado: (2017)

Untangling the evolutionary roots of lung cancer
por: Siddhartha Devarakonda, et al.
Publicado: (2019)

Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells.
por: Anke Bill, et al.
Publicado: (2012)

EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
por: Chad A Reade, et al.
Publicado: (2009)

Afatinib treatment in advanced non-small cell lung cancer
por: Hurwitz JL, et al.
Publicado: (2011)

Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
por: Chuan HUANG, et al.
Publicado: (2021)

First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
por: Gupta N, et al.
Publicado: (2013)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021)

Clinical development of nintedanib for advanced non-small-cell lung cancer
por: Takeda M, et al.
Publicado: (2015)

High quality of 58-month life in lung cancer patient with brain metastases sequentially treated with gefitinib and osimertinib
por: Zhang Ying, et al.
Publicado: (2021)

Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
por: Minami S, et al.
Publicado: (2015)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago G, et al.
Publicado: (2016)

Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy
por: Sugiura Y, et al.
Publicado: (2013)

Clinical use of crizotinib for the treatment of non-small cell lung cancer
por: Roberts PJ
Publicado: (2013)

Clinical and comparative utility of afatinib in non-small cell lung cancer
por: D'Arcangelo M, et al.
Publicado: (2014)

DNA repair capacity correlates with standardized uptake values from 18F-fluorodeoxyglucose positron emission tomography/CT in patients with advanced non–small-cell lung cancer
por: Xin (Eric) Jiang, et al.
Publicado: (2018)

Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
por: Yahua Wu, et al.
Publicado: (2022)

Clinical utility of ramucirumab in non-small-cell lung cancer
por: Uprety D
Publicado: (2019)

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
por: Nguyen KS, et al.
Publicado: (2012)

First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi S, et al.
Publicado: (2015)

Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells
por: Elisabete Cruz Da Silva, et al.
Publicado: (2021)

Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer
por: Jaclyn Flanigan, et al.
Publicado: (2010)

Emerging treatment options in the management of non-small cell lung cancer
por: Filosso PL, et al.
Publicado: (2011)

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions
por: Chie Morita, et al.
Publicado: (2021)

Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
por: Veldore VH, et al.
Publicado: (2018)

Cetuximab and biomarkers in non-small-cell lung carcinoma
por: Patil N, et al.
Publicado: (2012)

Functional promoter rs189037 variant of ATM is associated with decrease in lung diffusing capacity after irradiation for non–small-cell lung cancer
por: Jose Luis Lopez Guerra, et al.
Publicado: (2018)

The cost of treating advanced non-small cell lung cancer: estimates from the chinese experience.
por: Xiaohui Zeng, et al.
Publicado: (2012)

Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer
por: Fengying Wu, et al.
Publicado: (2021)

Clinical Outcomes of Chemotherapeutic Molecules as Single and Multiple Agents in Advanced Non-Small-Cell Lung Carcinoma (NSCLC) Patients
por: Ting Yoon Kwan, et al.
Publicado: (2021)

Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study
por: Rui Wan, et al.
Publicado: (2021)

Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance
por: Yu XW, et al.
Publicado: (2015)

Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer
por: Guo LG, et al.
Publicado: (2012)